Dendritic cells comprise a system of highly efficient antigen-presenting cells involved in the initiation of T cell responses. Herein, we investigated the role of the CD28 pathway during alloreactive T cell proliferation induced by dendritic-Langerhans cells (D-Lc) generated by culturing human cord blood CD34 § progenitor cells with granulocyte/macrophage colony-stimulating factor and tumor necrosis factor or. In addition to expressing CD80 (B7/BB1), a subset of D-Lc expressed B70/B7-2. Binding of the CTLA4-Ig fusion protein was completely inhibited by a combination of monoclonal antibodies (mAbs) against CD80 and B70/B7-2, indicating the absence of expression of a third ligand for CD28/CTLA-4. It is interesting to note that mAbs against CD86 completely prevented the binding of CTLA4-Ig in the presence of mAbs against CD80 and bound to a B70/B7-2-transfected fibroblast cell line, demonstrating that the B70/B7-2 antigen is identical to CD86. CD28 triggering was essential during D-Lc-induced alloreaction as it was inhibited by mAbs against CD28 (9 out of 11 tested). However, none of six anti-CDS0 mAbs demonstrated any activity on the D-I.c-induced aUoreaction, though some were previously described as inhibitory in assays using CD80-transfected cell lines. In contrast, a mAb against CD86 (IT-2) was found to suppress the D-Lc-dependent alloreaction by 70%. This inhibitory effect was enhanced to i>90% when a combination of anti-CD80 and anti-CD86 mAbs was used. The present results demonstrate that D-I.c express, in addition to CDS0, the other ligand for CTLA-4, CD86 (B70/B7-2), which plays a primordial role during D-Lc-induced alloreaction.
1A though presentation of antigen to TCR is necessary for the initiation of T cell activation, costimulatory signals delivered by the APC permit a full immune response. The CD28 pathway is regarded as an essential costimulus of T cell activation (1) . The coligation of the T cell CD28 receptors by the APC counter-receptors CD80 (B7/BB1) or the recently identified B70/B7-2 (2-5) results in IL-2 production and T cell proliferation (1, 2, 5) .
B70/B7-2 is expressed on resting monocytes and activated B and T cells and is upregulated on monocytes upon activation (2) (3) (4) (5) (6) . B7/BB1 and B70 expression on B ceils is upregulated by cross-linking MHC class II molecules (7) , surface membrane Ig (6), or CD40 antigen (2, 8) and cytokines such as IL-2 and IL-4 (9) . In vivo, blocking of the CD28/CTLA4 pathway results in T cell anergy, prolongation of graft survival, and blocking of B cell responses (10) (11) (12) .
Dendritic cells (DC 1) comprise a system of highly efficient 1 Abbreviations used in this paper: DC, dendritic cell; D-Lc, dendritic/ Langerhans cell.
APC that function to initiate immune responses (13) . In vivo, DC are involved in alloreactive T cell activation as occurs during transplant rejection, and in vitro, primary alloreactive T cell activation appears to be essentially mediated by DC (14) . Dendritic/Langerhans cells (D-Lc), generated by culturing human hematopoietic progenitor cells with GM-CSF and TNF-a, can induce strong proliferation of allogeneic T cells (15) . The present study was designed to investigate the expression and the function of CD28 counter-receptors on those in vitro-generated D-Lc. D-Lc were found to express both B7/BB1 and B70, the latter being identical to the recently clustered B cell antigen CD86. Importantly, this study also concluded that B70/CD86 is the crucial CD28 ligand involved in D-Lc-induced T cell alloreaction.
Materials and Methods
Hematopoietic Factors, Reagents, and Antibodies rhGM-CSF (sp act, 2 x 106 U/rag; Schering-Plough Research Institute, Kenilworth, NJ) was used at 100 ng/ml, rhTNF-c~ (sp act, 2 x 107 U/mg; Genzyme Corp., Cambridge, MA) was used at 2.5 ng/ml (16) . rhlL-2 (sp act, 3 x 106 U/rag; Amgen, Thousand Oaks, CA) was used at 10 U/ml. PHA (Murex Diagnostics, Dartford, England) was used at 0.1/~g/ml. Anti-CDla mAbs used were OKT6-FITC (Ortho, Raritan, NJ) and DMC1 (provided by Dr. C. Dezutter-Dambuyant, INSERM U346, Lyon, France). Anti-CD80 mAbs included L307 and L308 (from Dr. L. Lanier, DNAX Research Institute) (17, 18) , and mAb 104 (9) . Anti-B70 mAb (IT-2) was generated by Dr. M. Azuma (2) . Anti-CD28 mAb IOT28 was purchased from Immunotech (Marseille, France). The control fusion protein murine IL-4 receptor-Ig (mlL4R-Ig) was prepared as described (19) . The following reagents were obtained through the V International Workshop on Human Leukocyte Differentiation Antigens (Boston, MA, 3-7 November 1993): anti-CDf0, anti-CD28, anti-CD86 (FUN-1 and BU63) mAbs and the human CTLA-4 human Ig fusion protein (CTLA4-Ig; from Dr. P. S. Linsley Oncogen, Seattle, WA).
Collection and Purification of Cord Blood CD34 + Cells and Adult Blood T Cells
CD34 § Cells. Umbilical cord blood samples were obtained according to institutional guidelines. Cells bearing CD34 antigen were isolated from nonadherent mononuclear fractions through positive selection by indirect immune "panning" using anti-CD34 mAb (Imu-133.3; Immunotech). A second purification step was performed using a cocktail of mAbs, as described (20) . Thus, in all experiments, isolated cells were 95-99% CD34 + as judged by staining with anti-CD34 mAb.
CD4 § T Cells. Mononuclear cells, isolated from adult blood,
were depleted of adherent cells. CD4 § T lymphocytes were purified by immunomagnetic depletion using a cocktail of mAbs IOM2 (CD14), ION16 (CD16), ION2 (HLA-DR) (Immunotech), NKH1 (CD56), OKT8 (CD8) (Ortho), 4G7 (CD19), and mAb 89 (CD40). After two rounds of bead depletion, purity was routinely >95%.
Cell Cultures
Generation of D-La CD34 + cell cultures were established in the presence of GM-CSF and TNF-oe in medium consisting of RPMI-1640 (GIBCO BILL, Gaithersburg, MD) supplemented with 10% (vol/vol) FBS, 10 mM Hepes, 2 mM L-glutamine, 5 x 10 -s M 2-# ME, penicillin (100 U/ml), and streptomycin (100/~g/ml) (referred to as complete medium 
B70 Transfectants
Human B70 eDNA (2) in the pBJ expression vector (21) .:
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CDla CDla Figure 1 . In vitro-generated CDla + D-Lc express CDS0 (B7/BB1), B70/B7-2, and CD86. D-Lc were labeled either with CTLA4-1g (A), anti-CD80 (L307, L308, and mAbl04 were used and L307 is shown) (B), anti-BT0 (IT-2) (C), anti-CD86 (FUN-I) (E), or anti-CO86 (BU63) (F) revealed by PE-conjugated goat anti-human Ig (A) or PE-conjugated goat anti-mouse Ig (/3, C, E, and F). Then, after saturation in 2% mouse serum, cells were stained by FITC-conjugated anti-CDla (OKT6). In dot plot (D), cells were first labeled with anti-CD80 (L307) revealed by FITCconjugated goat anti-mouse Ig, saturated in 2% mouse serum and stained by hiotinylated anti-B70 (IT-2), revealed by PE-conjugated streptavidin. Quad limits were positioned on the negative control (data not shown).
Results are representative of more than 10 mcperiments.
Ligand for CD28 on Dendritic Cells as described (22) . B70-transfected L cells were selected for growth in I mg/ml G418 (Schering-Plough Research Institute), and transfectants with the highest cell surface density of B70 expression were isolated by flow cytometry.
Poesults
In Vitro-generated CDla + D-Lc Bind CTLA4-Ig through both B7/BB1 and B70/B7-2. We wondered whether D-Ix generated in vitro by culturing CD34 + cells for 12 d with GM-CSF + TNF-ot (12-d D-Lc) expressed CD80 as well as B70/B7-2. As shown in Fig. 1 most CDla + D-IX bound CTLA4-Ig (Fig. 1 A) and expressed CDS0 at two different intensity levels (low and high) (Fig. 1 B) . In contrast, only a subset of CDla + D-IX expressed B70/B7-2 ( Fig. 1 C) . Double staining with anti-CDS0 and anti-B70 mAbs showed that B70/B7-2 + cells comprised all CD80hig h and that all B70/B7-2-cells were CD80 l~ (Fig. 1 D) . In 10 independent experiments, 90 _+ 8% (80-100%) of CDla + D-IX were found to express CDS0 whereas only 55 _+ 20 (20-70%) expressed B70/B7-2.
As activated human B cells have been reported to express a third ligand for CD28/CTLA4 (6), we searched for this structure on D-IX by evaluating the effects of anti-CD80 and anti-B70 mAbs on the binding of CTLA4-Ig. 12-d D-IX were first incubated with one anti-CD80 mAb (L307, L308, mAb 104) or isotype control without or with the BT0-specific mAb IT-2, and then labeled with CTLA4-Ig (or mlL4R-Ig), revealed by PE-conjugated anti-human IgG. Cells were finally stained with FITC anti-CDla mAb (or FITC IgG1 control). Fig. 2 A shows that all CDla + ceils bound CTLA4-Ig and a subset (45-85%) still bound CTLA4-Ig after incubation with any of the four anti-CD80 mAb (only L307 is shown). In the presence of anti-B70 mAb, all CDla + cells still bound CTLA4-Ig though with a slightly decreased intensity (50% decrease in mean fluorescence intensity (MFI)). However, incubation of CDla + cells with anti-B70 mAb and any anti-CD80 mAb totally prevented the binding of CTLA4-Ig (Fig.   2 B) , thus excluding the presence of a third CD28/CTLA4 counterstructure. Taken together, these results demonstrate that in vitro-generated D-l.c express both CD80 and B70/B7-2 which account for all CTLA4-Ig binding sites.
B70/B7-2 Is Identical to CD86.
A phenotypic analysis of D-Lc with mAbs from the V International Workshop on Human Leukocyte Differentiation Antigens indicated that mAbs against CD86 (FUN-1 and BU63 ) stained CDla + D-Lc in a manner comparable to that of anti-B70 mAb (Fig.  1, C, E, and F) . In addition, kinetics studies of B70/B7-2 and CD86 expression indicated that the two molecules appeared concommitantly during generation and maturation of D-l.c (data not shown). Furthermore, as previously shown for mAb IT-2, mAbs against CD86 (FUN-1 is shown) used alone induced a slight decrease in intensity of CTLA4-Ig binding (50% decrease in MFI) (Fig. 2 C) , and combination of anti-CD86 and anti-CDS0 mAbs completely prevented the binding of CTLA4-Ig (Fig. 2 C) . Finally, the anti-CD86 mAbs (FUN-1 and BU63) bound to a B70-transfected L cell line but not to the control L cell line (Fig. 3) . Taken together, these results demonstrate that B70/B7-2 is identical to CD86.
CTLA 4-Ig Suppresses D-Lc-induced Alloreaction Mainly by
Blocking CD28/CD86 Interaction. Since, interactions between CD28/CTLA4 and their counter-receptors have been described as necessary for APC-dependent T cell activation, we investigated whether blocking of these interactions would also inhibit a D-ix-induced T cell aUoreaction. First, the CTLA4-Ig fusion molecule was used to interfere with CD28/CD28 ligand interactions that may occur during the D-Ix-induced alloreactire CD4 + T cell proliferation. As shown in Fig. 4 A (Exp. a control, never significantly affected any of the assays (Fig.   4 A, Exp. 1, and Fig. 4 B) . We then wondered whether a CD28-specific mAb (IOT28)
would also suppress a D-Lc-mediated alloreaction (Fig. 4) . Depending on the D-Lc concentration, IOT28 caused a 50-85% inhibition (35-90%, n = 6) of T cell DNA synthesis (Fig. 4 B) . This inhibitory effect was dose dependent with half-maximal effect at 0.5/~g/ml and maximal effect at 2.5 #g/ml (Fig. 4 A) .
It is interesting to note that the anti-CD80 mAb L307, which suppresses the development of CD8 cell cytotoxicity against CD80-transfected target cells (17) , failed to inhibit D-Lc-induced alloreaction even at concentrations as high as 10 #g/ml (Fig. 4, A and B) . To further strengthen these findings, all anti-CD28 and anti-CD80 antibodies available from the V Workshop on Human Leukocyte Differentiation Antigens were tested for their ability to affect D-Lc-induced alloreaction and to alter PHA + IL-2-dependent T cell proliferation. As shown in Fig. 5 , although able to bind to D-l_c (data not shown), none of the mAbs against CD80 demonstrated any activity on D-Lc-induced aUoreaction (Fig.  5, left) . Furthermore, these CD80-specific antibodies did not affect PHA + IL-2-induced T cell proliferation (Fig.   5, right) . In contrast, the CTLA4-Ig and 9 out of 11 mAbs against CD28 were found to inhibit by 55-85% the D-Lcinduced alloreaction. The CTLA4-Ig molecule has no effect on PHA + IL-2-dependent T cell proliferation, whereas, in accordance with their known costimulatory effects, the anti-CD28 mAbs that demonstrated blocking effect on D-Lcinduced alloreaction, costimulated T cell proliferation (1.8-2.2 fold enhancement) in the presence of PHA + IL-2. All anti-CD28 mAbs bound to T cell clones (data not shown), suggesting that the two mAbs lacking activity (M-T281 and CD28.4) recognized epitope(s) not involved in ligand binding. 3H TdR uptake (cpm xl 0 "3) Control isotype-matched mAbs did not significantly affect assays (Fig. 5) . In contrast, the anti-CD86 mAb IT-2 suppressed D-Lc-dependent alloreaction (60-80%, n = 3) by 70%. The inhibitory effect was dose-dependent with halfmaximal effect at 0.5/xg/ml and maximal effect at 2.5/zg/ml (Fig. 4 A, Exp. 2 ). In addition, a combination of anti-CD80
and anti-CD86 mAbs induced a nearly complete inhibition of T cell proliferation (88-100%, n = 6), even at high D-Lc numbers (data not shown). The suppressive effect of CTLA4-Ig (data not shown), anti-CD28, and anti-CD86 mAbs could be detected as early as after 2 d of cocuhure and was maintained throughout the culture period (Fig. 4 C) . The blocking effect of CTLA4-Ig and anti-CD86 mAb was specific for the D-Lc-induced alloreaction as they had no influence on PHA + IL-2-mediated T cell proliferation at any concentration or at any time tested (data not shown). Taken together, those results demonstrate that CD28 triggering is crucial during D-Lc-induced alloreaction, and occurs primarily through CD86 and secondarily through CD80 interactions.
Discussion
The present study was designed to determine the expression of the CD80 (B7/BB1) and B70/B7-2 accessory molecules on CD34 + progenitor-derived D-Lc and their contribution during D-Lc-induced T cell alloreactive proliferation. Using specific mAbs, CD80 was found to be expressed on virtually all CDla + D-Lc whereas B70/B7-2 expression was restricted to a smaller subset of CDla + D-Lc (50-70%). 1845 Caux et al.
This study also demonstrates formally the identity of B70/B7-2 with CD86, a newly clustered antigen initially identified as a B cell activation antigen with the FUN-1 (23) and BU63 mAbs. Functional studies demonstrated that CD28 triggering was a crucial event during D-Lc-mediated T cell alloreaction, a finding consistent with previous reports (24) (25) (26) . The present results further showed B70/CD86 as the major counter-receptor involved in CD28 triggering as a mAb against B70/B7-2 (IT-2) blocks by 50-80% the D-L-induced T cell aUoreaction whereas none of the nine tested anti-CD80 mAbs directly affect such a biological function. Yet, CDS0 does play a secondary role as a combination of anti-CD86 and anti-CD80 mAbs results in a complete abrogation of T cell activation. Such a finding suggests that no other accessory molecule, e.g., a third CD28 ligand (4, 6) , can replace these known CD28 ligands. Indeed, phenotypic analysis indicated that all CTLA4-Ig ligands on CDla + D-Lc were accounted for by CD80 and CD86 as a combination of mAbs directed against these two antigens completely inhibited the binding of the CTLA4-Ig fusion protein. Furthermore, although CD80 and CD86 antigens are upregulated on D-I.x: during CD40 triggering, a third CTLA4/CD28 counter-structure could not be detected after such activation (27) . The rationale for expression of two (or more) molecules mediating apparently similar effects on T cell activation is currently unknown. However, differences in the kinetics of upregulation during B cell activation (4, 6) , as well as its restricted expression on germinal center B cells (23) may argue for specific roles of CD86 versus CD80. During maturation of CD34 +-derived D-l.c, CD80 appears earlier than CD86 (data not shown) and expression of CD86 delineates two subsets among CDla § D-Lc (CD80 +, CD86 + and CD80 +, CD86-) which might represent different maturation or activation stages of D-l.c. In addition, CD86 is more strongly upregulated than CD80 during CD40 activation of CDla + D-l_c (27) . Such differential kinetics of expression during maturation and activation might suggest specific roles for CD80 versus CD86 during a T cell immune response.
The identification of CD86 is the major ligand for CD28 expressed on dendritic cells, will enable further manipulation of the CD28 pathway, potentially leading to a therapeutic strategy for the control of autoimmunity or transplantation tolerance. The importance of the CD28 counter-receptors in tumor immunity (28, 29) and the fact that D-Lc express spontaneously high levels of CD80 and CD86 antigens, represent new arguments to consider these in vitro generated D-Lc as an interesting material for development of immunotherapy strategies using tumor-associated antigens.
